Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743456 | 0.84 | APLNR (0.40) | ALDH1A1KDM4EPOLBMAPTTSHR | |
| SCHEMBL16516842 | 0.81 | APLNR (0.33) | ALDH1A1KDM4EPOLBMAPTTSHR | |
| SCHEMBL1132793 | 0.79 | MAPT (0.36) | TLR4ALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL11516575 | 0.79 | — | — | |
| SCHEMBL855428 | 0.79 | PSEN1 (0.43) | ALDH1A1KDM4EPOLBMAPTTSHR | |
| SCHEMBL16248382 | 0.77 | HTT (0.31) | TLR4 | |
| SCHEMBL12555452 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1338366 | 0.75 | ALDH1A1 (0.45) | TLR4ALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL16505741 | 0.73 | ALDH1A1 (0.36) | ALDH1A1KDM4EPOLBMAPTTSHR | |
| SCHEMBL27777564 | 0.72 | CYP3A4 (0.39) | ALDH1A1KDM4EPOLBMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459546-B1 | NEW BICYCLIC DIOXANES, THEIR PREPARATION AND THEIR USE AS FRAGRANT COMPOUNDS | MANE FILS V (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-8569518-B2 | Bicyclic dioxanes, their preparation and their use as fragrant compounds | V. MANE FILS (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20120165557-A1 | New Bicyclic Dioxanes, Their Preparation and Their Use as Fragrant Compounds | V. MANE FILS (FR) | 2012-06-28 | — | — | US | disclosed |
| EP-2459546-A1 | NEW BICYCLIC DIOXANES, THEIR PREPARATION AND THEIR USE AS FRAGRANT COMPOUNDS | V. Mane Fils (FR) | 2012-06-06 | — | — | EP | disclosed |
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-7981924-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| EP-1863787-B1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-2287159-A1 | New bicyclic dioxanes, their preparation and their use as organoleptic compounds | V.Mane Fils (FR) | 2011-02-23 | — | — | EP | disclosed |
| WO-2011013077-A1 | NEW BICYCLIC DIOXANES, THEIR PREPARATION AND THEIR USE AS FRAGRANT COMPOUNDS | V. MANE FILS (FR) | 2011-02-03 | — | — | WO | disclosed |
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-08-12 | — | — | US | disclosed |
| US-7723378-B2 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20080300294-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-12-04 | — | — | US | disclosed |
| EP-1954688-A1 | NOVEL THIOPHENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-07-24 | — | — | US | disclosed |
| EP-1863787-A1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007060626-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | NFATC1, ICOS, TPMT | TLR4 52/4885ALDH1A1 867/4885KDM4E 720/4885 |
| US-20080300294-A1 | Novel Thiophene Derivatives | TPMT, TSLP, NFATC1 | TLR4 99/4885ALDH1A1 2314/4885KDM4E 1127/4885 |
| US-20120165557-A1 | New Bicyclic Dioxanes, Their Preparation and Their Use as Fragrant Compounds | CBR3, CCNT1, C1R | TLR4 1690/4885ALDH1A1 922/4885KDM4E 2049/4885 |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | S1PR1, S1PR3, S1PR5 | TLR4 529/4885ALDH1A1 1893/4885KDM4E 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.